-
Publications
-
A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.
Ahmed M, Larson BK, Osipov A, Azad N, Hendifar A, Oncotarget 2024 Oct 15 741-747 -
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
von Itzstein MS, Yang Y, Wang Y, Hsiehchen D, Sheffield TY, Fattah F, Popat V, Ahmed M, Homsi J, Dowell JE, Rashdan S, Lohrey J, Hammers HJ, Hughes RS, Wang T, Xie Y, Gerber DE, Frontiers in immunology 2024 15 1351739 -
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.
Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Khan SA, Sultana N, Xie Y, Li QZ, Wakeland EK, Gerber DE, Journal for immunotherapy of cancer 2021 Jun 9 6 -
Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer.
Meng X, Ahmed M, Courtney KD, Arafat W, Ibrahim I, Margulis V, Nichols C, Bagrodia A, Frontiers in oncology 2021 11 724682 -
Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Popat V, Lu R, Ahmed M, Park JY, Xie Y, Gerber DE, The oncologist 2020 Mar -
GCNA Preserves Genome Integrity and Fertility Across Species.
Bhargava V, Goldstein CD, Russell L, Xu L, Ahmed M, Li W, Casey A, Servage K, Kollipara R, Picciarelli Z, Kittler R, Yatsenko A, Carmell M, Orth K, Amatruda JF, Yanowitz JL, Buszczak M, Developmental cell 2020 01 52 1 38-52.e10
-
A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.
Murtaza Ahmed, M.D.
- Internal Medicine - Hospital Medicine - University Hospitals
Education & Training
- Undergraduate - University of Texas at Dallas, Biology
- Medical School -